Chronic diabetic foot ulcers remain notoriously difficult to heal and 25% of these non-healing foot ulcers go on to amputation. The use of the new generation chemical wound healing commercial preparations, such as becaplermin (Regranex), platelet derived growth factors (PDGF) and synthetic skin graft preparations, as well as off-loading modalities that are commonly employed to heal diabetic foot ulcers, are not always successful. For example, the reported success rate of Regranex (becaplermin) in healing diabetic foot ulcers is approximately 48%. Full-body hyperbaric oxygen therapy in not new; however, topical use of hyperbaric oxygen therapy has only recently been reported. A small portable, sealed chamber designed to deliver a pressure greater that 100% surface equivalent oxygen to the wound site represents a new modality that can be used to heal diabetic ulcers.